Medicines and Poisons Act 2014

Medicines and Poisons Amendment Regulations 2020

SL 2020/214

Made by the Governor in Executive Council.

1. Citation
   These regulations are the *Medicines and Poisons Amendment Regulations 2020*.

2. Commencement
   These regulations come into operation as follows —
   (a) regulations 1 and 2 — on the day on which these regulations are published in the *Gazette*;
   (b) the rest of the regulations — on the day after that day.

3. Regulations amended
   These regulations amend the *Medicines and Poisons Regulations 2016*.

4. Regulation 142 amended
   In regulation 142(3) delete “record” and insert:

   information recorded under subregulation (2)

5. Regulation 143 amended
   In regulation 143(2) delete “record” and insert:

   information recorded under subregulation (1)

6. Regulation 143A inserted
   After regulation 143 insert:
143A. **Record of prescription of medicine that is Schedule 4 or 8 poison**

(1) An authorised health professional who prescribes a medicine that is a Schedule 4 or 8 poison for the treatment of a person or an animal must ensure that the following information is recorded on the clinical record for the person or animal —

(a) the name and address of the authorised health professional;
(b) the name, quantity, strength and form of the medicine prescribed;
(c) if the medicine is prescribed for the treatment of a person —
   (i) the name and address of the person; and
   (ii) if the medicine is a Schedule 8 poison — the date of birth of the person;
(d) if the medicine is prescribed for the treatment of an animal —
   (i) the name and address of the owner of the animal; and
   (ii) the species of the animal;
(e) the date on which the medicine is prescribed.

(2) The information recorded under subregulation (1) must —

(a) be provided to the CEO in the manner and form and at the times specified by the CEO; and
(b) in the case of a medicine that is a Schedule 4 poison — be kept for at least 2 years from the date on which the medicine is prescribed; and
(c) in the case of a medicine that is a Schedule 8 poison — be kept for at least 5 years from the date on which the medicine is prescribed; and
(d) be produced for inspection on the request of the CEO or an investigator.

7. **Schedule 2 amended**

In Schedule 2 insert in alphabetical order:

N-[(1S)-1-(AMINOCARBONYL)-2-METHYLPROPYL]-1-(5-FLUOROPENTYL)-1H-PYRROLO[2,3-B]PYRIDINE-3-CARBOXAMIDE
(5F-AB-P7AICA)
<table>
<thead>
<tr>
<th>Chemical Structure</th>
<th>CAS Registry Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-BUTYL-N-(2-PHENYLPROPAN-2-YL)-1H-INDOLE-3-CARBOXAMIDE (CUMYL-BICA)</td>
<td></td>
</tr>
<tr>
<td>1-(4-CYANOButYL)-N-(1-METHYL-1-PHENYLETHYL)-1H-INDAZOLE-3-CARBOXAMIDE (SGT-78;</td>
<td></td>
</tr>
<tr>
<td>4-CN-CUMYL-BINACA; CUMYL-CB-PINACA; CUMYL-CYBINACA; 4-CYANO CUMYL-BUTINACA)</td>
<td></td>
</tr>
<tr>
<td>1-CYCLOHEXYL-4-(1,2-DIPHENYLETHYL)PIPERAZINE (MT-45; IC-6)</td>
<td></td>
</tr>
<tr>
<td>2,5-DIHYDRO-2-(1-METHYL-1-PHENYLETHYL)-5-PENTYL-1H-PYRIDO[4,3-B]INDOL-1-ONE (CUMYL-PEGACLONE; SGT-151)</td>
<td></td>
</tr>
<tr>
<td>5-(5-FLUOROPENTYL)-2-(2-PHENYLPROPAN-2-YL)-2,5-DIHYDRO-1H-PYRIDO[4,3-B]INDOL-1-ONE (5F-CUMYL-PEGACLONE; 5F SGT-151)</td>
<td></td>
</tr>
<tr>
<td>2-(2-FLUOROPHENYL)-2-METHYLAMINO-CYCLOHEXANONE (2-FLUORODESCHLOROKETAMINE; 2FDCK)</td>
<td></td>
</tr>
<tr>
<td>METHYL 2-(9-(CYCLOHEXYLMETHYL)-9H-CARBAZOLE-3-CARBOXAMIDO)-3,3-DIMETHYLIBUTANOATE (MDMB-CHMCZCA)</td>
<td></td>
</tr>
<tr>
<td>METHYL 2-[1-(4-FLUOROBENZYL)-1H-INDOLE-3-CARBOXAMIDO]-3-METHYLBUTANOATE (MMB-FUBICA; AMB-FUBICA)</td>
<td></td>
</tr>
<tr>
<td>METHYL 2-[1-(4-FLUOROBUTYL)INDAZOLE-3-CARBONYL]AMINO]-3,3-DIMETHYLIBUTANOATE (4F-MDMB-BINACA; 4F-MDMB-BUTINACA)</td>
<td></td>
</tr>
<tr>
<td>METHYL 2-[1-(5-FLUOROPENTYL)INDOLE-3-CARBONYL]AMINO]-3,3-DIMETHYLIBUTANOATE (5-FLUORO MDMB-PICA; 5F-MDMB-PICA)</td>
<td></td>
</tr>
<tr>
<td>N-METHYL-1-(THIOPHEN-2-YL)PROPAN-2-AMINE (METHIOPROPAMINE; MPA)</td>
<td></td>
</tr>
<tr>
<td>N-(1-NAPHTHYL)-1-(5-FLUOROPENTYL)-1H-INDOLE-3-CARBOXAMIDE (5F-NNEI; 5F-MN-24)</td>
<td></td>
</tr>
</tbody>
</table>

M. INGLIS, Clerk of the Executive Council.